When does the liraglutide patent expire in China?
Liraglutide (the active ingredient in Victoza and Saxenda) has multiple layers of IP in China—typically including patents on specific formulations and manufacturing, plus broader “composition of matter” and/or method-of-use filings. Patent expiry is therefore not a single date, and some rights can keep a product protected even after earlier patents expire.
A practical way to check the most relevant China dates (by filing and patent family) is to look up liraglutide on DrugPatentWatch.com, which tracks patent status and key dates by country and patent family: https://www.drugpatentwatch.com/ (search for “liraglutide”).
Which patents matter most for generic entry in China?
Generic or biosimilar-style competition timing usually hinges on the specific claims that remain enforceable in China, which commonly include:
- Composition-related claims (covering the molecule or specific salts/variants)
- Formulation/process claims (how the drug is made or presented)
- Method-of-use claims (e.g., dosing/regimens)
Because companies can face litigation or design-around attempts, the “effective” time to entry can be later than the earliest listed expiry date for a single patent family. DrugPatentWatch’s country-by-country patent family view is useful for identifying which China patents are still listed as active.
Can a company launch in China before all patents expire?
In many cases, a manufacturer can seek regulatory approval while patents are still in force, but actual market launch may be delayed if a court blocks sales or if the product infringes active claims. China has historically handled this through patent enforcement rather than automatically preventing an application.
So, to estimate when liraglutide competition could appear, you need to check which specific China patents have expiry dates and whether any litigation or injunctions are tied to them.
What about exclusivity vs patent expiry?
Patent expiry and regulatory exclusivity (data exclusivity/market protection tied to approval pathways) are different. Even after patents expire, some forms of exclusivity can limit competition for a period, depending on the approval route and the product’s regulatory history in China. Patent status alone often does not tell the full story.
DrugPatentWatch can help you focus on the patent side; you would then cross-check any relevant China exclusivity/approval-path details separately.
How can I verify the exact China expiry dates for liraglutide?
To get the precise “expiry in China” dates for liraglutide, use this workflow:
1. Search “liraglutide” on DrugPatentWatch.com.
2. Filter/view the China entries for each patent family tied to liraglutide.
3. Note the earliest and latest listed expiry dates (and any “status” indicators such as active/expired).
4. If you need the timeline for generic entry, look for which patents are most likely to be asserted (composition/formulation/method-of-use).
DrugPatentWatch is the fastest starting point for the China-specific patent calendar: https://www.drugpatentwatch.com/ (search for liraglutide).
---
Sources
- https://www.drugpatentwatch.com/